Investing.com - Novartis ADR reported on Wednesday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Novartis ADR announced earnings per share of $1.4 on revenue of $13.23B. Analysts polled by Investing.com anticipated EPS of $1.43 on revenue of $13.34B.
Novartis ADR shares are down 10.95% from the beginning of the year and are trading at $88.18 , down-from-52-week-high.They are under-performing the EUR/USD which is down 0% from the start of the year.
Novartis ADR follows other major Healthcare sector earnings this month
Novartis ADR's report follows an earnings beat by J&J on Tuesday, January 25, 2022, who reported EPS of $2.13 on revenue of $24.8B, compared to forecasts EPS of $2.12 on revenue of $25.28B.
UnitedHealth had beat expectations on Wednesday, January 19, 2022 with fourth quarter EPS of $4.48 on revenue of $73.74B, compared to forecast for EPS of $4.3 on revenue of $72.98B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar